Zepbound: How Eli Lilly’s Lucky Break Fueled a $600B Weight-Loss Empire – Bloomberg

After DiMarchi left, research on GLP-1s for obesity at Lilly “just ceased,” he says. Over the next two decades weight-loss drugs went “in and out of …